“From just a regular business sense, we can’t raise prices to offset some of our supply cost problems,” says David Morris, MD.
At the LUGPA 2022 Annual Meeting, David Morris, MD, Urology Associates, Nashville, TN, discussed challenges facing urology practices in an interview with Urology Times. In this video, he focuses on the difficulties urology practices have faced amid the ongoing inflation crisis.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.